Tectonic Therapeutic Completes Enrollment in Key Phase 2 Trial for TX45; Results Expected Early 2027
TECX sits 95% above its 52-week low of $14.385.
Summary
Tectonic Therapeutic has completed enrollment for its TX45 APEX Phase 2 clinical trial, which is evaluating the drug in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This milestone confirms the trial is on schedule and moves the company closer to potential therapeutic options for a condition with significant unmet medical need. The company previously reported increased R&D spending on clinical trials in its Q1 2026 10-Q filing. Topline results from the APEX trial are anticipated in early Q1 2027.
At the time of this announcement, TECX was trading at $28.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $529.3M. The 52-week trading range was $14.39 to $36.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.